BrainStorm Cell Therapeutics Announces Dana-Farber Will Produce NurOwn for US-based Phase II Trial

BrainStorm Cell Therapeutics Inc. is preparing to conduct a Phase II trial to test the safety, and tolerability, as well as collect preliminary efficacy data on their NurOwn™ stem cell technology for the treatment of ALS in the United States (US) later in 2013. Although BrainStorm is still awaiting Food and Drug Administration (FDA) approval for the trail, they have already secured three clinical trial sites in the US including the University of Massachusetts (UMass), Massachusetts General Hospital (MGH), and the Mayo Clinic. On April 8 BrainStorm announced that they are working with The Connell and O’Reilly Cell Manipulation Core Facility at Dana-Farber Cancer Institute to provide “cGMP-compliant clean room facilities for production of BrainStorm’s NurOwn™ stem cell candidate.” Under this agreement, Dana-Farber will provide NurOwn to the UMass and MGH Phase II clinical trial sites.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail